Forgot your password?

Forgot your username?

database > company
CeQur
Medical Devices & Tech
Rue Igor-Stravinsky 2
Montreux, 1820, Switzerland
phone:+41(0)21 965 46 46
fax:+41(0)21 965 46 49
Symbol Private
Founded 2008
Employees
www.cequr.net
Research Sector Medical Devices & Tech
Summary Description
Novel, minimally invasive drug delivery platform for continuous administration of insulin indicated for type 2 diabetes.
Management
Eric Milledge, Chairman; James Peterson, CEO and Vice-Chairman; Douglas Gunthardt, CFO; Mads Dall, Executive Vice President of Strategy and Business Development; Peter Gravesen, Executive Vice President of Regulatory Affairs; Michael Hassman, Senior Vice President of Manufacturing & Global Supply Chain; Jay Warner, Senior Vice President of Marketing & Sales
Keywords
Diabetes, Insulin drug delivery, minimally invasive drug patch



Comment | Printable Version | Modify profile |
Updated: Mar. 15, 2013

Description
CeQur has developed a wearable insulin delivery device that delivers basal and bolus doses subcutaneously, thus granting flexibility to patients of type 2 diabetes mellitus who could benefit from intensive insulin therapy. The Companyâ??s lead product candidate is a small insulin patch infuser that easily attaches to the patientâ??s abdominal area with a safe and secure adhesive backing and includes a disposable insulin reservoir that attaches to a reusable electronic messenger; once in place, insulin is delivered subcutaneously through a fine, soft tube or cannula from the reservoir that is changed by the patient every few days. The device is designed to use just one type of insulin for both basal and bolus dosing. Multiple rates will be available for basal dosing, and bolus dosing will be available on-demand at the push of a button. This earlier-stage biotechnology company is dedicated to helping the 200 million-plus people worldwide with type 2 diabetes stay on track and in control of their disease by granting them freedom from the inconvenience and discomfort of multiple daily injections.
Products / Services

The CeQur device is a patch-on infuser, which delivers basal insulin as well as meal-related bolus insulin at the simple push of a button - anywhere at any time, for several days. The system consist...

view more
Technology / Differentiation
The company's insulin delivery technology enables the continuous delivery of insulin to diabetic patients. The company's apparatus serves as a discreet wearable patch infuser that delivers precise amounts of insulin to patients, both in basal doses, as well as in bolus doses on-demand at the push of a button. The company's minimally invasive subcutaneous route of drug administration precludes the use of the existing injection-based insulin regimens that are burdensome to patients due to their painful nature, which can significantly lower patient compliance.
Market / Customers

It is estimated that there are 285 million people with diabetes in the world in 2010. Out of these 90-95% have type 2 diabetes. As their disease progress around 50% will eventually have to inject insu...

view more
Competitors / Substitutes / Alternatives
The Cequr insulin delivery device will be among the first in this new category of 'patch-on' insulin delivery devices for people with Type 2 diabetes, who today have to inject themselves with insulin pens and syringes.
Status
The current series B raise will take the company through to full scale commercial launch.
Analyst Coverage
An important drawback of current diabetes treatment regimens is patient compliance, particularly for insulin injections that are painful and must also be timely administered. Cequr has developed an innovative technological platform to address this concern, actualizing a minimally invasive wearable drug patch infuser that provides relatively painless, continuous subcutaneous delivery of insulin in basal doses, as well on-demand doses at the push of a button.